Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 259Cyclophosphamide 238Etoposide 114Prednisone 97Vincristine 96Doxorubicin 96Peripheral Blood Stem Cell Transplantation 95fludarabine phosphate 87Filgrastim 80Cytarabine 61Lenalidomide 60Mycophenolic Acid 59Melphalan 59Radiotherapy 58Busulfan 52Cyclosporine 50Carmustine 49Whole-Body Irradiation 48Tacrolimus 46Methotrexate 42Antilymphocyte Serum 38Gemcitabine 33Ifosfamide 32Carboplatin 32fludarabine 31Dexamethasone 31polatuzumab vedotin 29Granulocyte Colony-Stimulating Factor 29CT-P10 28Methylprednisolone 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Large B-Cell, Diffuse × resiniferatoxin × Clear all
NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Case Comprehensive Cancer Center

Phase 1 Not yet recruiting
15 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡